Yuanyuan M. Zhao

No. 95 Wenhua Road
Zhengzhou, 450002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 250 publications

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.

Journal: BMC cancer

Published: August 13, 2026

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

Journal: Journal for immunotherapy of cancer

Published: August 05, 2026

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

Solving the cooling flow problem with combined jet-wind AGN feedback.

Solving the cooling flow problem with combined jet-wind AGN feedback.

Journal: Science advances

Published: July 03, 2026

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.

Journal: JAMA

Published: June 17, 2026

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial.

Journal: Journal for immunotherapy of cancer

Published: June 03, 2026

Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial.

Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial.

Journal: Drug design, development and therapy

Published: May 30, 2026

ZBP1-driven pyroptosis-associated alveolar macrophages exacerbate epithelial dysfunction in sepsis.

ZBP1-driven pyroptosis-associated alveolar macrophages exacerbate epithelial dysfunction in sepsis.

Journal: Cell death & disease

Published: March 28, 2026

A Nomogram to Predict Day-7 Total Bilirubin in Hepatitis B Virus-Related Cirrhosis: An Early Treatment-Response Assessment Tool.

A Nomogram to Predict Day-7 Total Bilirubin in Hepatitis B Virus-Related Cirrhosis: An Early Treatment-Response Assessment Tool.

Journal: Infection and drug resistance

Published: March 24, 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: March 20, 2026

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Histopathological distribution characteristics and prognostic value of cancer-associated fibroblasts in non-small cell lung cancer

Histopathological distribution characteristics and prognostic value of cancer-associated fibroblasts in non-small cell lung cancer

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: February 13, 2026

Showing 1-12 of 250

Last Updated: 09/26/2026